XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
USD ($)
Agreement
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Agreement
Jun. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue $ 225,250 $ 188,411 $ 344,748 $ 318,935  
AstraZeneca [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Number of collaboration agreements | Agreement 2   2    
Revenue $ 15,960 $ 59,501 $ 27,645 $ 83,926  
Deferred contract revenue $ 1,900   $ 1,900   $ 0
AstraZeneca [Member] | Revenue [Member] | Strategic Partner [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Concentration percentage 7.00% 32.00% 8.00% 26.00%  
AstraZeneca [Member] | Minimum [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Cumulative payments received $ 920,000   $ 920,000    
WAINUA [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Number of collaboration agreements | Agreement 1   1    
Maximum amount of payments receivable over term of collaboration $ 3,600,000   $ 3,600,000    
Maximum amount of upfront payments over term of collaboration 200,000   200,000    
Maximum amount of development milestone payments over term of collaboration 485,000   485,000    
Maximum amount of sales milestone payments over term of collaboration 2,900,000   $ 2,900,000    
WAINUA [Member] | Minimum [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Royalty percentage received on net sales of medicine     20.00%    
Next payment to be achieved $ 30,000   $ 30,000    
Cardiovascular, Renal and Metabolic Diseases [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Number of collaboration agreements | Agreement 1   1